Mbayame Nd Niang1, Jonathan D Sugimoto2,3,4, Aldiouma Diallo5, Bou Diarra5, Justin R Ortiz6, Kristen D C Lewis7, Kathryn E Lafond8, M Elizabeth Halloran2,9, Marc-Alain Widdowson2,6,10, Kathleen M Neuzil6, John C Victor7. 1. Institut Pasteur de Dakar, Dakar, Senegal. 2. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 3. Seattle Epidemiologic Research and Information Center, Department of Veterans Affairs Office of Research and Development, Seattle, Washington, USA. 4. Department of Epidemiology, University of Washington, Seattle, Washington, USA. 5. VITROME, Institut de Recherche Pour le Développement, Dakar, Senegal. 6. Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA. 7. PATH, Seattle, Washington, USA. 8. Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 9. Department of Biostatistics, University of Washington, Seattle, Washington, USA. 10. Institute of Tropical Medicine, Antwerp, Belgium.
Abstract
BACKGROUND: We report results of years 2 and 3 of consecutive cluster-randomized controlled trials of trivalent inactivated influenza vaccine (IIV3) in Senegal. METHODS: We cluster-randomized (1:1) 20 villages to annual vaccination with IIV3 or inactivated poliovirus vaccine (IPV) of age-eligible residents (6 months-10 years). The primary outcome was total vaccine effectiveness against laboratory-confirmed influenza illness (LCI) among age-eligible children (modified intention-to-treat population [mITT]). Secondary outcomes were indirect (herd protection) and population (overall community) vaccine effectiveness. RESULTS: We vaccinated 74% of 12 408 age-eligible children in year 2 (June 2010-April 11) and 74% of 11 988 age-eligible children in year 3 (April 2011-December 2011) with study vaccines. Annual cumulative incidence of LCI was 4.7 (year 2) and 4.2 (year 3) per 100 mITT child vaccinees of IPV villages. In year 2, IIV3 matched circulating influenza strains. The total effectiveness was 52.8% (95% confidence interval [CI], 32.3-67.0), and the population effectiveness was 36.0% (95% CI, 10.2-54.4) against LCI caused by any influenza strain. The indirect effectiveness against LCI by A/H3N2 was 56.4% (95% CI, 39.0-68.9). In year 3, 74% of influenza detections were vaccine-mismatched to circulating B/Yamagata and 24% were vaccine-matched to circulating A/H3N2. The year 3 total effectiveness against LCI was -14.5% (95% CI, -81.2-27.6). Vaccine effectiveness varied by type/subtype of influenza in both years. CONCLUSIONS: IIV3 was variably effective against influenza illness in Senegalese children, with total and indirect vaccine effectiveness present during the year when all circulating strains matched the IIV3 formulation. CLINICAL TRIALS REGISTRATION: NCT00893906. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
BACKGROUND: We report results of years 2 and 3 of consecutive cluster-randomized controlled trials of trivalent inactivated influenza vaccine (IIV3) in Senegal. METHODS: We cluster-randomized (1:1) 20 villages to annual vaccination with IIV3 or inactivated poliovirus vaccine (IPV) of age-eligible residents (6 months-10 years). The primary outcome was total vaccine effectiveness against laboratory-confirmed influenza illness (LCI) among age-eligible children (modified intention-to-treat population [mITT]). Secondary outcomes were indirect (herd protection) and population (overall community) vaccine effectiveness. RESULTS: We vaccinated 74% of 12 408 age-eligible children in year 2 (June 2010-April 11) and 74% of 11 988 age-eligible children in year 3 (April 2011-December 2011) with study vaccines. Annual cumulative incidence of LCI was 4.7 (year 2) and 4.2 (year 3) per 100 mITT child vaccinees of IPV villages. In year 2, IIV3 matched circulating influenza strains. The total effectiveness was 52.8% (95% confidence interval [CI], 32.3-67.0), and the population effectiveness was 36.0% (95% CI, 10.2-54.4) against LCI caused by any influenza strain. The indirect effectiveness against LCI by A/H3N2 was 56.4% (95% CI, 39.0-68.9). In year 3, 74% of influenza detections were vaccine-mismatched to circulating B/Yamagata and 24% were vaccine-matched to circulating A/H3N2. The year 3 total effectiveness against LCI was -14.5% (95% CI, -81.2-27.6). Vaccine effectiveness varied by type/subtype of influenza in both years. CONCLUSIONS: IIV3 was variably effective against influenza illness in Senegalese children, with total and indirect vaccine effectiveness present during the year when all circulating strains matched the IIV3 formulation. CLINICAL TRIALS REGISTRATION: NCT00893906. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Authors: Suzanne E Ohmit; Mark G Thompson; Joshua G Petrie; Swathi N Thaker; Michael L Jackson; Edward A Belongia; Richard K Zimmerman; Manjusha Gaglani; Lois Lamerato; Sarah M Spencer; Lisa Jackson; Jennifer K Meece; Mary Patricia Nowalk; Juhee Song; Marcus Zervos; Po-Yung Cheng; Charles R Rinaldo; Lydia Clipper; David K Shay; Pedro Piedra; Arnold S Monto Journal: Clin Infect Dis Date: 2013-11-13 Impact factor: 9.079
Authors: Danuta M Skowronski; Naveed Z Janjua; Suzana Sabaiduc; Gaston De Serres; Anne-Luise Winter; Jonathan B Gubbay; James A Dickinson; Kevin Fonseca; Hugues Charest; Nathalie Bastien; Yan Li; Trijntje L Kwindt; Salaheddin M Mahmud; Paul Van Caeseele; Mel Krajden; Martin Petric Journal: J Infect Dis Date: 2014-01-19 Impact factor: 5.226
Authors: Núria Torner; Ana Martínez; Luca Basile; M Angeles Marcos; Andrés Antón; M Mar Mosquera; Ricard Isanta; Carmen Cabezas; Mireia Jané; Angela Domínguez; The Pidirac Sentinel Surveillance Program Of Catalonia Journal: Hum Vaccin Immunother Date: 2014-11-01 Impact factor: 3.452
Authors: Dominik Mertz; Shaza A Fadel; Po-Po Lam; Dat Tran; Jocelyn A Srigley; Sandra A Asner; Michelle Science; Stefan P Kuster; Johannes Nemeth; Jennie Johnstone; Justin R Ortiz; Mark Loeb Journal: Euro Surveill Date: 2016-10-20
Authors: Lauren C Ramsay; Sarah A Buchan; Robert G Stirling; Benjamin J Cowling; Shuo Feng; Jeffrey C Kwong; Bryna F Warshawsky Journal: BMC Med Date: 2019-01-10 Impact factor: 8.775
Authors: Gail E Potter; Nicole Bohme Carnegie; Jonathan D Sugimoto; Aldiouma Diallo; John C Victor; Kathleen M Neuzil; M Elizabeth Halloran Journal: J R Stat Soc Ser C Appl Stat Date: 2021-09-22 Impact factor: 1.680
Authors: Ryan E Malosh; Joshua G Petrie; Amy Callear; Rachel Truscon; Emileigh Johnson; Richard Evans; Latifa Bazzi; Caroline Cheng; Mark S Thompson; Emily T Martin; Arnold S Monto Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 20.999